.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires inclusion of patients along with MASLD as well as measurement of liver end results in cardio-- renal-- metabolic tests, when records suggest mechanistically plausible benefits and also professional safety-- and outlines factors for trial style and governing approval.